<DOC>
	<DOCNO>NCT00398645</DOCNO>
	<brief_summary>This study design determine investigational drug effective safe individual asthma .</brief_summary>
	<brief_title>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma .</brief_title>
	<detailed_description>A Randomized , Double-Blind , Placebo-Controlled , Parallel Group , Multicenter Study Evaluate Efficacy Safety GW685698X 200mcg Twice Daily , GW685698X 200mcg 400mcg Once Daily Morning , GW685698X 200mcg 400mcg Once Daily Evening Compared Placebo 8 Weeks Adolescent Adult Subjects ( 12 Years Age Older ) Persistent Asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : Type Subject : Outpatient Age : 12 year age old Visit 1 ( ³18 year age old local regulation regulatory status study medication permit enrollment adult ) . Gender : Male eligible female Females eligible participate currently nonpregnant nonlactating . To eligible entry study , female childbearing potential must commit consistent correct use acceptable method birth control , define follow : Male partner sterile prior female subject 's entry study sole sexual partner female subject , Implants levonorgestrel , Injectable progestogen , Oral contraceptive ( either combine estrogen/progestin progestin ) , Any intrauterine device ( IUD ) document failure rate le 1 % per year , Doublebarrier method spermicide plus mechanical barrier ( e.g. , spermicide plus male condom spermicide female diaphragm ) , The contraceptive transdermal patch , Ortho Evra ( subject less 198 pound ) , Female subject enrolled plan become pregnant time study participation . A urine pregnancy test require subject visit , Female subject enrolled plan become pregnant time study participation . A urine pregnancy test require subject visit , Female subject enrolled plan become pregnant time study participation . A urine pregnancy test require subject visit , Females childbearing potential sexually active must commit complete abstinence intercourse throughout clinical trial , period trial account elimination drug ( minimum six day ) , Asthma Diagnosis : Asthma define National Institutes Health [ National Institutes Health , 2002 ; GINA , 2005 ] . Severity Disease : A best AM FEV1 50 % 80 % predict value Visit 1 base `` Standardization Lung Function Tests '' [ European Respiratory Society , 1993 ] standard 18 year old Polgar [ Polgar , 1971 ] standard 12 17 year race adjust AfricanAmericans [ American Thoracic Society , 1991 ] . Reversibility Disease : Demonstrated ³12 % 200mL reversibility FEV1 within 30 minute follow 200 400mcg albuterol/salbutamol inhalation aerosol ( one nebulized albuterol/salbutamol treatment ) Visit 1 . If subject fails demonstrate increase FEV1 ³12 % 200mL , subject eligible study allow rescreen . Concurrent AntiAsthma Therapy : Subjects must use inhaled corticosteroid least 3 month prior Visit 1 maintain stable dose four week prior Visit 1 one follow dos : AntiAsthma Therapy Maximum Daily Dose ( mcg/day ) Fluticasone propionate MDI CFC/HFA ≤220mcg1/≥250mcg2 Fluticasone propionate DPI 200mcg Beclomethasone dipropionate 420mcg1/500mcg2 Beclomethasone dipropionate HFA 160mcg1/200mcg2 Budesonide DPI 400mcg Flunisolide 1000mcg Triamcinolone acetonide 1000mcg Mometasone furoate 200mcg Ciclesonide 160mcg1/200mcg2 1 . Exactuator dose : dose deliver lung 2 . Exvalve dose : dose express valve ShortActing Beta2Agonist : All subject must able replace shortacting beta2agonists albuterol/salbutamol inhalation aerosol Visit 1 use asneeded duration study . Subjects must able withhold inhale shortacting betasympathomimetic bronchodilator least 6 hour prior study visits.Note : Nebulized albuterol/salbutamol allow study exception use reversibility test Visit 1 . The use albuterol/salbutamol DISKUS/ACCUHALER device allow study . Informed Consent : All subject must able willing give write informed consent take part study . Compliance : Subjects must able comply study requirement . Exclusion criterion : History LifeThreatening Asthma : History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnia , respiratory arrest hypoxic seizure . AntiAsthma Medications : Asthma medication list must use prior Visit 1 require interval list , take study : Within 24 hour Visit 1 : Oral shortacting beta2agonists : Within 2 week Visit 1 : Combination therapy contain inhaled beta2agonists ICS asthma ( e.g. , fluticasone propionate/salmeterol combination , budesonide/formoterol combination ) ; Slowrelease bronchodilator ( e.g. , aminophylline , theophylline ) ; Anticholinergics ; Longacting beta2agonists ( e.g. , salmeterol ) ; Ketotifen ; Nedocromil sodium ; Sodium cromoglycate ; Oral longacting beta2agonists . Within 4 week Visit 1 : Antileukotrienes include suppressor leukotriene production antagonist . Within 12 week Visit 1 : Systemic , oral , parenteral , depot corticosteroid ; AntiIgE ( e.g. , omalizumab ) . Other Medications : The medication list must use prior Visit 1 require interval indicate , take study : Within 4 week Visit 1 : Known potent inhibitor CYP3A4 ( e.g. , ritonavir , ketoconazole ) Respiratory Infection : History respiratory tract infection within 4 week Visit 1 . In addition , subject must exclude , infection occur Visits 1 2 . Asthma Exacerbation : History asthma exacerbation within 4 week Visit 1 , asthma exacerbation require oral corticosteroid within 3 month Visit 1 , hospitalization due asthma exacerbation within 6 month Visit 1 . Investigational Medications : A subject must use investigational drug within 30 day prior Visit 1 within ten halflives ( t1/2 ) prior investigational study ( ever longer two ) concurrently study . Concurrent Diseases/Abnormalities : Historical current evidence clinically significant uncontrolled disease include , limited : cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , pulmonary disease ( include , confine chronic bronchitis , emphysema , bronchiectasis need treatment , cystic fibrosis , bronchopulmonary dysplasia , chronic obstructive pulmonary disease ) . Significant defined disease , opinion investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . Oropharyngeal Examination : A subject eligible runin he/she evidence oropharyngeal candidiasis Visit 1 . Drug Allergy : Any adverse reaction include immediate delay hypersensitivity beta2agonist , sympathomimetic drug , intranasal , inhale , systemic corticosteroid therapy . Milk Protein Allergy : History severe milk protein allergy . Immunosuppressive Medications : A subject must use , require use , immunosuppressive medication study . Note : Immunotherapy treatment allergy allow study provide initiated prior Visit 1 subject maintain stable daily dose throughout study period . Attendance : A subject eligible he/she his/her parent legal guardian infirmity , disability , geographical location seem likely ( opinion Investigator ) impair compliance aspect study protocol schedule visit study center compliance study medication procedure ( e.g. , completion daily diary ) . Neurological psychiatric disease history drug alcohol abuse would interfere subject 's proper completion protocol requirement exclude study participation . Tobacco Use : A subject may use tobacco product within past one year ( i.e. , cigarette , cigar , pipe tobacco ) must historical use &gt; 10 pack year ( e.g. , 20 cigarettes/day 10 year ) . Affiliation Investigator 's Site : A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GW685698X</keyword>
	<keyword>Adults</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Asthma</keyword>
	<keyword>Adolescents</keyword>
</DOC>